###begin article-title 0
PIKfyve Regulation of Endosome-Linked Pathways
###end article-title 0
###begin p 1
###xml 93 94 93 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 94 95 94 95 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1044 1045 1044 1045 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1045 1046 1045 1046 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
The phosphoinositide 5-kinase (PIKfyve) is a critical enzyme for the synthesis of PtdIns(3,5)P2, that has been implicated in various trafficking events associated with the endocytic pathway. We have now directly compared the effects of siRNA-mediated knockdown of PIKfyve in HeLa cells with a specific pharmacological inhibitor of enzyme activity. Both approaches induce changes in the distribution of CI-M6PR and trans-Golgi network (TGN)-46 proteins, which cycles between endosomes and TGN, leading to their accumulation in dispersed punctae, whilst the TGN marker golgin-245 retains a perinuclear disposition. Trafficking of CD8-CI-M6PR (retromer-dependent) and CD8-Furin (retromer-independent) chimeras from the cell surface to the TGN is delayed following drug administration, as is the transport of the Shiga toxin B-subunit. siRNA knockdown of PIKfyve produced no defect in epidermal growth factor receptor (EGFR) degradation, unless combined with knockdown of its activator molecule Vac14, suggesting that a low threshold of PtdIns(3,5)P2 is necessary and sufficient for this pathway. Accordingly pharmacological inhibition of PIKfyve results in a profound block to the lysosomal degradation of activated epidermal growth factor (EGF) and Met receptors. Immunofluorescence revealed EGF receptors to be trapped in the interior of a swollen endosomal compartment. In cells starved of amino acids, PIKfyve inhibition leads to the accumulation of the lipidated form of GFP-LC3, a marker of autophagosomal structures, which can be visualized as fluorescent punctae. We suggest that PIKfyve inhibition may render the late endosome/lysosome compartment refractory to fusion with both autophagosomes and with EGFR-containing multivesicular bodies.
###end p 1
###begin p 2
###xml 183 184 183 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 287 290 287 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">(1)</xref>
###xml 332 335 332 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">(2)</xref>
###xml 363 366 363 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">(3)</xref>
###xml 689 691 689 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">(4</xref>
###xml 692 694 692 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5)</xref>
###xml 939 942 939 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">(6)</xref>
3-phosphoinositides control the identity and dynamics of endocytic compartments, through the recruitment of multiple effector proteins containing specific recognition domains. PtdIns3P is generated by the class III PtdIns 3-kinase, hVps34, and is concentrated on early/sorting endosomes (1). It is required for receptor trafficking (2) and membrane fusion events (3), through its contribution to recruitment of several proteins containing FYVE or phox homology phox homology (PX) domains. The FYVE domain proteins early endosomal autoantigen-1 (EEA1) and hepatocyte growth factor regulated tyrosine kinase substrate (Hrs) are required for endosome fusion and receptor sorting respectively (4,5), whilst the PX domain containing Sorting Nexin 1 (SNX1) is a component of the retromer complex that mediates retrieval of the cation-independent mannose-6-phosphate receptor (CI-M6PR) from the endocytic pathway to the trans-Golgi network (TGN) (6).
###end p 2
###begin p 3
###xml 7 8 7 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 62 63 62 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 63 64 63 64 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">(7</xref>
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8">8)</xref>
###xml 273 276 273 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">(9)</xref>
###xml 299 300 299 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 300 301 300 301 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 359 363 359 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">(10)</xref>
###xml 414 418 414 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">(11)</xref>
###xml 519 522 519 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">(12</xref>
###xml 523 526 523 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">14)</xref>
###xml 220 225 <span type="species:ncbi:4932">yeast</span>
###xml 353 358 <span type="species:ncbi:4932">yeast</span>
###xml 423 428 <span type="species:ncbi:4932">yeast</span>
PtdIns3P is also a precursor for the generation of PtdIns(3,5)P2 by the FYVE domain containing PtdIns 5-kinase, PIKfyve (7,8). The enzyme was first linked to the endosomal pathway by the observation that deletion of the yeast homologue results in markedly swollen vacuoles (9). Levels of PtdIns(3,5)P2 increase due to various stresses, osmotic shock in yeast (10) and ultraviolet (UV) radiation in mammalian cells (11). In yeast and mammalian cells PIKfyve interaction with Vac14 serves to stimulate enzymatic activity (12-14).
###end p 3
###begin p 4
###xml 18 27 18 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bone fide</italic>
###xml 52 53 52 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 53 54 53 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 74 78 74 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">(15)</xref>
###xml 192 196 192 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">(16)</xref>
###xml 376 377 376 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 393 394 393 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 394 395 394 395 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 480 484 480 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">(17)</xref>
###xml 550 554 550 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">(18)</xref>
###xml 643 647 643 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">(19)</xref>
###xml 108 113 <span type="species:ncbi:4932">yeast</span>
###xml 528 533 <span type="species:ncbi:4932">yeast</span>
Identification of bone fide effectors of PtdIns(3,5)P2 has proven elusive (15). The best established is the yeast protein Svp1/Atg18, for which deletion results in a swollen vacuole phenotype (16). The mammalian homologues of Svp1 are the WD repeat domain containing, phosphoinositide-interacting 1 (WIPI-1) and WIPI-2 proteins. WIPI-1 (also known as WIPI-49) binds to PtdIns3P and PtdIns(3,5)P2, and altering its expression levels leads to changes in the distribution of CI-M6PR (17). Svp1/Atg18 was identified in a screen for yeast autophagy genes (18) and WIPI-1 has also been shown to associate with starvation-induced autophagic vacuoles (19).
###end p 4
###begin p 5
###xml 86 108 86 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Caenorhabditis elegans</italic>
###xml 110 121 110 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C. elegans)</italic>
###xml 248 252 248 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">(20)</xref>
###xml 266 276 266 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 413 417 413 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">(21)</xref>
###xml 583 587 583 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">(22)</xref>
###xml 774 778 774 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">(23)</xref>
###xml 86 108 <span type="species:ncbi:6239">Caenorhabditis elegans</span>
###xml 110 120 <span type="species:ncbi:6239">C. elegans</span>
###xml 266 276 <span type="species:ncbi:7227">Drosophila</span>
###xml 429 433 <span type="species:ncbi:10090">mice</span>
Various studies have examined the effects of manipulating PIKfyve and Vac14 levels. A Caenorhabditis elegans (C. elegans) mutant hypomorphic for the PIKfyve homologue was suggested to possess a defect in retrieval of membrane from mature lysosomes (20). Deletion of Drosophila PIKfyve yields cells with enlarged endosomes and a defect in degradation of Wingless and Notch, without any apparent signalling defects (21). Vac14 -/- mice show a neurodegenerative defect, whilst at the cellular level, both large vacuoles and trapping of the CI-M6PR in endosomal compartments are evident (22). siRNA knockdown of PIKfyve is only partially effective, but also leads to defects in CI-M6PR trafficking whilst the degradation of epidermal growth factor receptor (EGFR) is unaffected (23).
###end p 5
###begin p 6
###xml 157 161 157 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">(24)</xref>
Jefferies et al. have recently characterized a novel inhibitor of PIKfyve, YM201636, which provides the first opportunity for acute inhibition of the enzyme (24). This can allow discrimination of direct effects due to enzyme inhibition rather than longer-term adaptive responses of cells to knockout, or of protein functions unconnected to enzymatic activity. We now provide further characterization of the cellular effects of a PIKfyve inhibitor (MF4) pharmacologically similar to YM201636, which we have directly compared with knockdown of PIKfyve alone or in combination with Vac14. Our data reveal acute effects upon receptor tyrosine kinase (RTK) trafficking that reconcile with observations from model organisms, and provide new insight into PIKfyve involvement in cycling between TGN and endosomes as well as the autophagy pathway.
###end p 6
###begin title 7
Results
###end title 7
###begin title 8
PIKfyve inhibition creates swollen vacuoles inaccessible to fluid phase marker
###end title 8
###begin p 9
###xml 155 159 143 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">(23)</xref>
###xml 606 610 582 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">(24)</xref>
###xml 613 622 589 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Figure 1E</xref>
###xml 657 659 633 635 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 667 668 643 644 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 734 735 709 710 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 822 823 796 797 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 841 842 810 811 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 861 862 826 827 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1316 1331 1272 1287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Figure 1A and B</xref>
###xml 1481 1490 1437 1446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Figure 1C</xref>
###xml 1541 1542 1497 1498 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1673 1682 1629 1638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Figure 1D</xref>
###xml 1081 1092 <span type="species:ncbi:3704">horseradish</span>
Knockdown of PIKfyve in HeLa cells creates swollen vacuoles visible by phase contrast light microscopy in approximately30% of cells as previously reported (23). We could obtain highly efficient knockdown of the PIKfyve activator protein Vac14 but this only produced the vacuole phenotype at very low penetrance (approximately3%) and did not augment the effect of PIKfyve knockdown on vacuole formation (not shown). MF4 is chemically similar to the recently described specific PIKfyve inhibitor YM201636 by Jefferies et al., with the only difference being that MF4 lacks an amino group on the pyridine ring (24), (Figure 1E). MF4 inhibited PIKfyve with an IC50 of 23 nm, whereas an inactive analogue MF2 showed no activity even at 5 mum. Corresponding MF4 values for class I PtdIns 3-kinases which we determined are 0.25 mum (p110alpha), 1 mum (p110beta), 0.9 mum (p110gamma) and 0.8 muM (p110delta). Application of MF4 gives a vacuolar phenotype in all cells within 4 h. Electron microscopic analysis indicates that the large phase lucent vacuoles are inaccessible to internalized horseradish peroxidase (HRP), but they do become surrounded by a second class of smaller (but still swollen) HRP-containing vacuoles, positive for early (EEA1) or late endosomal markers [lysosome-associated membrane protein (LAMP-2)] (Figure 1A and B), which we will henceforth refer to as 'swollen endosomes'. The retromer components Vps26 and SNX1 also associate with swollen endosomal structures (Figure 1C). MF4 does not appreciably reduce cellular PtdIns3P levels or its cellular distribution, as assessed by immunofluorescence labelling of cells for this lipid with a GST-2xFYVE probe (Figure 1D).
###end p 9
###begin title 10
PIKfyve inhibition creates large swollen vacuoles inaccessible to fluid phase marker
###end title 10
###begin p 11
###xml 34 35 34 35 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 217 238 217 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Materials and Methods</italic>
###xml 291 292 291 292 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 812 813 811 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
HeLa cells were treated with 800 nm PIKfyve inhibitor (MF4) for 4 h prior to either fixation and staining with a variety of markers by immunofluorescence, or uptake of HRP for 1 h, fixation and processing for EM (see Materials and Methods for details). Wortmannin was added to cells at 100 nm for 30 min. A) MF4-mediated inhibition of PIKfyve causes the formation of swollen vacuoles that are inaccessible to internalized HRP. These vacuoles are surrounded by a second class of smaller HRP-containing vacuoles. B) Both early and late endosomal markers are associated with distinct swollen endosomes that surround these vacuoles. C) Retromer components Vps26 and SNX-1 also associate with swollen endosomal compartments. Scale bars = 10 mum. D) The PtdIns 3-kinase inhibitor Wortmannin ablates endosomal PtdIns(3)P staining, whilst MF4 treatment has no significant effect. Scale bars = 20 mum. E) Chemical structure of MF4 (PIKfyve inhibitor) and MF2 (inactive analogue).
###end p 11
###begin title 12
Disruption of endosome to TGN trafficking
###end title 12
###begin p 13
###xml 194 198 194 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">(23)</xref>
###xml 351 355 351 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">(25)</xref>
###xml 699 714 699 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Figure 2A and B</xref>
###xml 859 863 859 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">(26)</xref>
###xml 924 933 924 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Figure 2C</xref>
###xml 991 994 991 994 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 1051 1060 1051 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Figure 2D</xref>
###xml 1212 1221 1212 1221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Figure 2E</xref>
PIKfyve has been implicated in the control of the retromer-mediated pathway between endosomes and the TGN through siRNA studies of CI-M6PR distribution with respect to the marker protein TGN-46 (23). Certain aspects of these studies may be complicated by the fact that TGN-46 itself undergoes a cycling itinerary, which partially overlaps with ciM6PR (25). We have now analyzed the steady-state distribution of TGN-46, CI-M6PR and golgin-245 following individual knockdown of PIKfyve, hVac14, a combination of the two and the PIKfyve inhibitor. Knockdown of PIKfyve or its inhibition leads to a more dispersed distribution of CI-M6PR but also of TGN-46, whilst knockdown of Vac14 has little effect (Figure 2A and B). In cells where the TGN46 has been highly dispersed, there is little co-localization with CI-M6PR or with an alternative TGN marker golgin-245 (26), which retains its characteristic perinuclear localization (Figure 2C). Under conditions where TGN-46 is highly dispersed, the cis-Golgi marker GM130 retains its ribbon-like disposition (Figure 2D), characteristic of intact Golgi structure. No changes in levels of CI-M6PR or of retromer components are seen as a consequence of PIKfyve inhibition (Figure 2E).
###end p 13
###begin title 14
Inhibition of PIKfyve causes a disruption in steady-state distribution of ciM6PR and TGN46
###end title 14
###begin p 15
###xml 65 66 65 66 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 509 512 509 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
HeLa cells were treated with 40 nM siRNA oligos for 72 h or 800 nm MF4 for 4 h. Both knockdown and inhibition of PIKfyve alter the steady-state localization of ciM6PR, whereas Vac14 knockdown and MF2 (inactive analogue of the PIKfyve inhibitor MF4) have no effect (A and B). The markers fragment into distinct vesicular compartments, which show little co-localization. The distribution of a second TGN resident protein golgin-245 is unaffected and retains its characteristic perinuclear localization (D). The cis-golgi marker GM130 also retains it's ribbon-like disposition (E). There is no change in the levels of ciM6PR or retromer components upon treatment with PIKfyve inhibitor (F). Scale bars = 20 mum.
###end p 15
###begin p 16
###xml 144 148 144 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">(27)</xref>
###xml 492 496 492 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">(28)</xref>
###xml 672 681 672 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig03">Figure 3A</xref>
###xml 804 813 804 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig03">Figure 3B</xref>
###xml 905 920 905 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig04">Figure 4A and B</xref>
###xml 1072 1081 1072 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig04">Figure 4C</xref>
Cell surface exposed CI-M6PR can be retrieved to the TGN following endocytosis, and Shiga toxin follows an overlapping retromer-dependent route (27). We have followed trafficking of a chimeric CD8-CI-M6PR along this route following application of an anti-CD8 antibody and of fluorescently labelled Shiga toxin B-subunit. Furthermore, we have followed the trafficking of a CD8-Furin chimeric protein, which also traffics from the cell surface to the TGN, but in a retromer-independent fashion (28). Following PIKfyve inhibition, internalized CD8-CI-M6PR and CD8-Furin both can reach a TGN compartment, but show slower rates of accumulation at this perinuclear destination (Figure 3A). In cells which show highly dispersed TGN-46 punctae, these do not co-localize with CD8-CI-M6PR at the final time-point (Figure 3B). Shiga toxin can reach the perinuclear TGN as judged by co-localization with golgin-245, (Figure 4A and B) following PIKfyve inhibition, but its accumulation there, is impeded and co-localization with dispersed TGN-46 positive punctae can also be observed (Figure 4C).
###end p 16
###begin title 17
PIKfyve inhibition causes a perturbation in the uptake of the Shiga toxin B-subunit
###end title 17
###begin p 18
###xml 130 131 130 131 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
Uptake of the Shiga toxin B-subunit was examined in HeLa cells using a Cy3-labelled StxB construct, following treatment with 800 nm MF4 PIKfyve inhibitor. Cy3-STxB retrieval to a perinuclear localization is also delayed in cells treated with PIKfyve inhibitor (A), but ultimately reaches a TGN localization, as judged by co-localization with golgin-245 (B). In cells where TGN46 is highly dispersed, co-localization with Cy3-STxB can be observed, indicative of the fact that these two proteins may traffic on a similar retrieval pathway (C). Scale bars = 20 mum.
###end p 18
###begin title 19
PIKfyve inhibition causes a delay in CD8-ciM6PR and CD8-Furin retrieval
###end title 19
###begin p 20
###xml 139 140 139 140 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
Uptake of CD8 antibody in HeLa M cell lines stably expressing CD8-ciM6PR and CD8-Furin was examined following treatment of cells with 800 nm MF4 PIKfyve inhibitor. Both Furin and ciM6PR retrieval to a trans-Golgi localization is delayed upon inhibition of PIKfyve (A). At the terminal uptake time-point, in cells where TGN46 is highly fragmented, there is negligible co-localization with CD8-ciM6PR (B). Scale bars = 20 mum.
###end p 20
###begin title 21
Downregulation of RTKs
###end title 21
###begin p 22
###xml 109 113 109 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">(23)</xref>
###xml 266 281 266 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig05">Figure 5A and B</xref>
###xml 402 420 402 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig05">Figure 5C, D and E</xref>
###xml 632 636 632 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">(29)</xref>
###xml 752 761 752 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig05">Figure 5G</xref>
###xml 925 936 925 936 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophilia</italic>
###xml 948 952 948 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">(21)</xref>
###xml 1148 1152 1148 1152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">(30)</xref>
###xml 1353 1362 1353 1362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig05">Figure 5F</xref>
###xml 1398 1399 1398 1399 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1419 1420 1419 1420 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1503 1508 1503 1504 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 1541 1545 1537 1541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">(24)</xref>
###xml 1686 1691 1678 1679 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 1696 1700 1684 1685 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
PIKfyve siRNA studies of EGF-induced EGFR downregulation have not revealed any defect in EGFR downregulation (23). Our data concur with these previous studies, but we noticed that when combined with Vac14 knockdown a modest defect in EGFR downregulation is evident (Figure 5A and B). A far more effective block to EGFR and also c-Met downregulation was seen following application of PIKfyve inhibitor (Figure 5C, D and E). Fluorescence examination of EGFR distribution shows that residual receptor following PIKfyve inhibition is concentrated in punctate structures which frequently co-localize with the early endosomal marker EEA1 (29). In many cases EGFR can be visualized in the interior of endosomes decorated with EEA1 on their limiting membrane (Figure 5G). Thus acute pharmacological inhibition has revealed an important function of PIKfyve in mammalian cells that provides some reconciliation with data obtained with Drosophilia knock-outs (21), which indicated defects in receptor downregulation. If activated receptor was retained at the limiting membrane of endosomes, one may expect more prolonged signalling following acute activation (30). We do not see this when we examine activation of mitogen-activated protein kinase (MAPK) or AKT/protein kinase B (PKB). Rather we see a dampening of AKT signalling at later time-points, e.g. 30 min (Figure 5F). Although IC50 values of MF4 (23 nm) and YM210636 (33 nm) are similar towards PIKfyve, we obtain less selectivity over PtdIns 3-kinase p110alpha than that reported for YM210636 (24). To be certain that the observed effects on EGFR degradation were not as a result of p110alpha inhibition, specific inhibitors for both p110alpha and beta were used. Both inhibitors caused a significant reduction in phosphorylation of AKT/PKB but had no effect on EGFR degradation (data not shown). These results in combination with the observation that MF4 does not cause a reduction in initial EGF-dependent phosphorylation of AKT/PKB, suggest that the effects on EGFR degradation are not due to a non-specific inhibition of class 1 PtdIns 3-kinases.
###end p 22
###begin title 23
Acute inhibition of PIKfyve affects downregulation of tyrosine kinase receptors
###end title 23
###begin p 24
###xml 96 97 95 96 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1093 1094 1088 1089 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
HeLa cells were treated with siRNA oligos against the indicated proteins (A and B), or with 3 mum PIKfyve inhibitor (C and D) or the indicated doses of inhibitor (E). Serum-starved cells were stimulated with 100 ng/mL EGF or HGF for the indicated times. A) Individual knockdown of PIKfyve or Vac14 did not affect the degradation of either EGFR or c-Met. B) A combined knockdown of PIKfyve with Vac14 caused a modest delay in receptor downregulation. C) Treatment with PIKfyve inhibitor caused a severe delay in EGFR. D) c-Met downregulation. E) Concentration dependence of MF4 on EGFR downregulation after 120 min EGF stimulation. F) pMAPK and pAKT signalling is not prolonged following treatment with PIKfyve inhibitor, pAKT signalling is dampened at later time-points. alpha-tubulin is used as a protein loading control. G) Immunofluorescence images demonstrating the accumulation of EGFR in PIKfyve inhibitor and combined knockdown treated HeLa cells. HeLa cells were transfected with 40 nM of the indicated oligos over 72 h, then serum-starved overnight, and following treatment with 800 nm PIKfyve inhibitor (in place of siRNA treatment; where indicated), were stimulated with 100 ng/mL EGF for 4 h. Following fixation with 3% PFA in PBS cells were labelled with anti-EGFR and anti-EEA-1. A proportion of the EGFR can be seen in the interior of swollen early endosomal compartments (G). Scale bars = 20 mum.
###end p 24
###begin title 25
Role of PIKfyve in autophagy
###end title 25
###begin p 26
###xml 7 8 7 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 133 134 133 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 134 135 134 135 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 250 251 250 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 251 252 251 252 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 252 256 252 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">(16)</xref>
###xml 450 454 450 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">(31)</xref>
###xml 673 688 673 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig06">Figure 6A and B</xref>
###xml 740 749 740 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig06">Figure 6C</xref>
###xml 180 185 <span type="species:ncbi:4932">yeast</span>
PtdIns3P generated by the PtdIns 3-kinase Vps34 is required for initial steps of autophagosome formation, but the role of PtdIns(3,5)P2 is less well established. The Atg18 gene in yeast binds both 3-phosphoinositides with a preference for PtdIns(3,5)P2(16). One signature for the accumulation of autophagosomes is the enrichment of a faster migrating form (LC3 II) of the autophagy protein LC3, following its conjugation to phosphatidyl-ethanolamine (31). Whilst, neither Vac14 nor PIKfyve knockdown had any significant influence on starvation-induced accumulation of GFP-LC3-II (data not shown), inhibitor treatment led to a significant increase, as judged biochemically (Figure 6A and B) and by the visualization of GFP-labelled punctae (Figure 6C). Addition of the PIKfyve inhibitor, MF4 did not significantly increase the accumulation of GFP-LC3 in the presence of leupeptin, a condition in which the degradation of GFP in the late endosome/autolysosome should be reduced. This indicates that MF4 treatment does not increase the rate of formation of autophagosomes but instead interferes with their consumption.
###end p 26
###begin title 27
Inhibition of PIKfyve leads to an increase in starvation-induced GFP-LC3 lipidation
###end title 27
###begin p 28
###xml 616 617 616 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 623 626 623 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p &lt;</italic>
HEK293A cells stably transfected with GFP-LC3 were treated with MF4 PIKfyve inhibitor or an inactive analogue (MF2) for 4 h prior to replacement of fresh growth medium (fed) or Earles' balanced salt solution (EBSS) for 2 h (starved). Cells were subsequently lysed or processed for immunofluorescence. A) Western blot on triplicate samples indicating the levels of GFP-LC3 I and II in fed and starved cells upon treatment with MF4 and with or without the protease inhibitor Leupeptin. B) Quantitative analysis of the ratio of GFP-LC3 II to total GFP-LC3 from A. PIKfyve inhibition causes a statistically significant (n = 3, p < 0.01, T-test) accumulation of lipidated GFP-LC3 upon starvation-induced autophagy. C) Immunofluorescence analysis of GFP-LC3 II punctae formation following starvation-induced autophagy. The accumulation of GFP-LC3 II positive punctae can be observed following treatment with PIKfyve inhibitor. Scale bars = 20 mum.
###end p 28
###begin title 29
Discussion
###end title 29
###begin p 30
###xml 246 247 246 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 247 248 247 248 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 755 759 755 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">(23)</xref>
###xml 1534 1538 1534 1538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">(24)</xref>
###xml 1650 1654 1650 1654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">(22)</xref>
###xml 1597 1601 <span type="species:ncbi:10090">mice</span>
Previous studies in mammalian cells have assessed phenotypes arising from siRNA knockdown. These have the following drawbacks; (i) PIKfyve has proven hard to completely deplete, so that residual enzymatic activity could provide enough PtdIns(3,5)P2 particularly if the enzyme is controlled by a positive feedback loop, (ii) it is not clear if phenotypes observed are because of loss of enzyme activity or of some other function of the protein and (iii) depletion is very gradual, so that any phenotype may constitute a very indirect consequence of protein loss over a prolonged time period. Nevertheless, these studies and our current study, have shown that the distribution of proteins which traffic between the sorting endosome and the TGN is perturbed (23). This result is recapitulated by acute pharmacological inhibition. One of these proteins is TGN-46, which, because it is also cycling along this pathway cannot be reliably used as a TGN marker under these conditions. Golgin-245, another TGN marker, shows significantly less perturbation following PIKfyve inhibition. Dispersed TGN-46 punctae produced by PIKfyve inhibition do not co-localize with golgin-245, suggesting that TGN-46 may accumulate in another compartment that forms part of its itinerary. Whilst Jeffries et al.suggest that the steady-state distribution of CI-M6PR is not drastically altered following treatment with YM201636, their experiments were performed in a different cell line (NIH3T3) and other assays for retrieval on this pathway were not examined (24). In accordance with our data, a recent study of Vac14 -/- mice showed a similar defect in CI-M6PR distribution (22).
###end p 30
###begin p 31
As well as the steady-state distribution, the kinetics of transport from the cell surface via the endosome to the TGN is delayed for several proteins (CD8-CI-M6PR, CD8-Furin, Shiga Toxin), which may utilize retromer-dependent (CD8-CI-M6PR, Shiga toxin) and retromer-independent (CD8-Furin) sorting mechanisms from the endosome. Interestingly, retrieval to the TGN is delayed and not completely blocked following loss of PIKfyve activity, suggesting that either cargo may traffic on alternate, less efficient pathways or that enzymatic activity is rate-limiting for this process but not essential.
###end p 31
###begin p 32
###xml 21 25 21 25 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">(23)</xref>
###xml 341 344 341 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">(20</xref>
###xml 345 348 345 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">21)</xref>
###xml 477 478 477 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 478 479 478 479 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 585 594 585 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig04">Figure 4B</xref>
###xml 630 631 630 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 631 632 631 632 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Knockdown of PIKfyve (23) or of Vac14 (this study) does not significantly affect EGFR degradation rates, consistent with previous studies. This observation has been difficult to reconcile with knockout phenotypes in model organisms which have suggested a critical role for PIKfyve in receptor degradation and formation of terminal lysosomes (20,21). We reasoned that in the circumstance of incomplete depletion, combining Vac14 and PIKfyve knockdown should suppress PtdIns(3,5)P2 to a greater extent than PIKfyve alone. This condition revealed a modest inhibition of EGFR degradation (Figure 4B), suggesting a role for PtdIns(3,5)P2 synthesis, but with a relatively low threshold value. Consistent with this observation, pharmacological inhibition of PIKfyve, at concentrations which do not produce any major perturbation in the levels of other 3-phosphoinositides, revealed a strong block to both EGFR and c-Met downregulation, as judged by western blotting and by immunofluorescence. The appearance of EGFR in the interior of swollen endosomes positive for EEA1 suggests that the major impediment is not a defect in sorting to luminal vesicles, but may reflect a failure of multivesicular bodies to fuse with the degradative late endosome/lysosomal compartment.
###end p 32
###begin p 33
###xml 18 19 18 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 75 79 75 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b32">(32)</xref>
###xml 115 116 115 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 116 117 116 117 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 271 275 271 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">(33)</xref>
###xml 563 567 563 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">(24)</xref>
###xml 1251 1252 1251 1252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1252 1253 1252 1253 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1499 1500 1499 1500 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1500 1501 1500 1501 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1614 1615 1614 1615 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1631 1632 1631 1632 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1632 1633 1632 1633 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1633 1641 1633 1641 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1641 1645 1641 1645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">(17)</xref>
###xml 1466 1471 <span type="species:ncbi:4932">yeast</span>
A role for PtdIns3P in the formation of autophagosomes is well established (32), but the part played by PtdIns(3,5)P2 is less clear. We observe that PIKfyve inhibition leads to an accumulation of lipidated GFP-LC3 on punctate structures, characteristic of autophagosomes (33). This could reflect an increased rate of production of autophagosomal structures or a decreased rate of their consumption by fusion with lysosomes. Taking this data together with the observation of Jefferies et al., that autophagic breakdown of proteins is reduced by PIKfyve inhibition (24), we favour the second interpretation. Thus, both effects on the autophagy pathway and of EGFR downregulation could be explained by a common mechanism, through which PIKfyve inhibition either renders an acceptor late endosome/lysosome compartment refractory to fusion or leads to a defect in the acidification necessary for lysosomal degradation. Although not quantitative, Acridine Orange accumulation in endocytic punctae, indicative of acidification, is similar in both MF4-treated and control cells, although it does not accumulate in the highly swollen vacuoles which appear disconnected from the endocytic pathway (data not shown). Two general models can explain how PtdIns(3,5)P2 effects are mediated; (i) by recruitment of effector molecules with specific lipid binding domains and (ii) allosteric regulation of resident endocytic proteins, e.g. enzyme or channel activity. Although Svp1 in yeast is an authentic PtdIns(3,5)P2 sensor it is less clear for its mammalian orthologues WIPI-1 and WIPI-2. WIPI-1, like Svp1 can bind both PtdIns3P and PtdIns(3,5)P2in vitro(17) whilst the lipid binding-properties of WIPI-2 are unknown. Other candidate effector proteins remain to be identified.
###end p 33
###begin p 34
###xml 353 354 353 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 354 355 354 355 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
In summary, juxtaposition of siRNA knockdown of PIKfyve with pharmacological inhibition links the observed siRNA phenotype of disrupted endosome to TGN trafficking, with enzymatic activity. However, pharmacological inhibition reveals further defects on the receptor degradation and autophagy pathway, suggesting that relatively low levels of PtdIns(3,5)P2 are permissive for these pathways.
###end p 34
###begin title 35
Materials and Methods
###end title 35
###begin title 36
Antibodies and other reagents
###end title 36
###begin p 37
###xml 167 185 167 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Limulus polyphemus</italic>
###xml 1151 1154 1151 1154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">(4)</xref>
###xml 1568 1572 1568 1572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">(34)</xref>
###xml 1630 1634 1630 1634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">(35)</xref>
###xml 0 6 <span type="species:ncbi:9986">Rabbit</span>
###xml 18 23 <span type="species:ncbi:9606">human</span>
###xml 67 74 <span type="species:ncbi:9986">rabbits</span>
###xml 167 185 <span type="species:ncbi:6850">Limulus polyphemus</span>
###xml 250 255 <span type="species:ncbi:9940">Sheep</span>
###xml 268 273 <span type="species:ncbi:9940">sheep</span>
###xml 300 305 <span type="species:ncbi:9940">sheep</span>
###xml 456 462 <span type="species:ncbi:9986">Rabbit</span>
###xml 645 650 <span type="species:ncbi:10090">Mouse</span>
###xml 688 694 <span type="species:ncbi:9986">rabbit</span>
###xml 746 751 <span type="species:ncbi:10090">mouse</span>
###xml 924 928 <span type="species:ncbi:9925">goat</span>
###xml 977 982 <span type="species:ncbi:10090">Mouse</span>
###xml 1023 1028 <span type="species:ncbi:10090">Mouse</span>
###xml 1097 1103 <span type="species:ncbi:9986">Rabbit</span>
###xml 1300 1305 <span type="species:ncbi:10090">mouse</span>
###xml 1426 1431 <span type="species:ncbi:10090">mouse</span>
Rabbit polyclonal human Vac14 antibodies were raised by immunizing rabbits with the N-terminal amino acids of Vac14 (HLEVRHQRSGRGDHLDRR), conjugated via a cysteine to Limulus polyphemus haemocyanin (Covance) and affinity purified on peptide columns. Sheep anti-TGN46, sheep anti-GM130 antibodies and sheep anti-GFP were generous gifts of Vas Ponnambalam (University of Leeds, UK) Francis Barr and Ian Prior (both University of Liverpool, UK) respectively. Rabbit polyclonal anti-PIKfyve and anti-CI-M6PR antibodies were generous gifts from Lois Weisman (University of Michigan, USA) and Paul Luzio (Cambridge Institute of Medical Research, UK). Mouse monoclonal anti-Met (25H2) antibody, rabbit monoclonal phosphorylated AKT (pAkt) (Ser 473) and mouse monoclonal phosphorylated MAPK (pMAPK) (Thr 202, Tyr 204) antibodies were from Cell Signalling. Monoclonal anti-EGFR R1 was from Cancer Research UK Laboratories (CRUK) and goat polyclonal anti-EGFR 1005 were from Santa Cruz. Mouse monoclonal anti-tubulin was from Sigma. Mouse monoclonal anti-golgin 245 (p230) antibody was from BD Biosciences. Rabbit polyclonal anti-EEA-1 was previously described (4). Secondary antibodies were from Molecular Probes and Licor Biosciences. HeLa M cell lines stably expressing CD8-CI-M6PR and CD8-Furin along with mouse monoclonal CD8 antibody were generous gifts from Matthew Seaman (Cambridge Institute of Medical Research, UK). Purified mouse EGF was obtained from J. Smith, Liverpool, UK. 2GL9 cells, HEK293A cells stably transfected with GFP-LC3 have been previously described (34). GST-2xFYVE (Hrs) vector was a gift from Harald Stenmark (35) Following production in bacteria it was isolated with Glutathione Sepharose and then biotinylated with Sulfo-NHS-LC-Biotin (Pierce, UK). Purified PIKfyve protein was a kind gift from Frank Cooke (UCL, UK).
###end p 37
###begin title 38
Synthesis and characterization of MF4 and MF2
###end title 38
###begin p 39
###xml 120 124 120 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">(36)</xref>
###xml 224 225 224 225 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 227 228 227 228 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 373 374 373 374 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 376 377 376 377 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 471 479 471 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vacuo</italic>
###xml 675 676 675 676 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 697 699 697 699 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">20</sub>
###xml 700 702 700 702 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">15</sub>
###xml 703 704 703 704 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 705 706 705 706 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 707 708 707 708 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 900 901 900 901 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 906 907 906 907 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 990 994 984 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">(37)</xref>
###xml 1028 1029 1022 1023 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1031 1032 1025 1026 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1071 1080 1065 1074 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vacuo.</italic>
###xml 1167 1168 1161 1162 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1170 1171 1164 1165 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1253 1254 1247 1248 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1336 1337 1330 1331 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1358 1360 1352 1354 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">25</sub>
###xml 1361 1363 1355 1357 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">20</sub>
###xml 1364 1365 1358 1359 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sub>
###xml 1366 1367 1360 1361 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1428 1432 1422 1426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">(36)</xref>
###xml 1467 1468 1461 1462 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1489 1491 1483 1485 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">26</sub>
###xml 1493 1495 1487 1489 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">22</sub>
###xml 1496 1497 1490 1491 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sub>
###xml 1498 1499 1492 1493 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Synthesis of the PIKfyve inhibitor (hereafter designated MF4) and its inactive analogue, MF2 is described below. PI-103 (36) (200 mg, 0.57 mmol) and 2,6-di-tert-butyl-4-methylpyridine (136 mg, 0.66 mmol) were dissolved in CH2Cl2 (20 mL) and cooled on ice. Triflic anhydride (0.3 mL, 0.63 mmol) was added drop-wise and the reaction was warmed to room temperature. Further CH2Cl2 was added (10 mL) and the reaction was allowed to proceed overnight. The solvent was removed in vacuo and the product was purified by silica gel flash chromatography with 25% EtOAc:Hexanes to yield 67 mg (24% yield). Liquid chromatography-electrospray ionisation-mass spectrometry (LC-ESI-MS) [MH]+ m/z calculated for C20H15F3N4O5S 481.1, found 480.9. This product (67 mg, 0.14 mmol), cesium carbonate (64 mg, 0.20 mmol) and nicotinamide (21 mg, 0.17 mmol) were added to dioxane (4 mL). Xantphos (10 mg, 0.016 mmol) and Pd2(dba)3 (5 mg, 0.006 mmol) were added and the reaction was heated to 100degreesC for 24 h (37). The reaction was diluted with CH2Cl2, filtered and the solvent was removed in vacuo. The product was purified by silica gel chromatography using a gradient of 2-3% MeOH:CH2Cl2 and by reverse phase high performance liquid chromotography (HPLC) using a MeCN/H2O/0.1% trifluoroacetate (TFA) solvent system to give a white solid. LC-ESI-MS [MH]+ m/z calculated for C25H20N6O3453.2, found 453.0. MF2 was prepared similarly using PIK-112 (36) in place of PI-103. LC-ESI-MS [MH]+ m/z calculated for C26 H22N6O2451.2, found 451.4.
###end p 39
###begin title 40
In vitro kinase assay
###end title 40
###begin p 41
###xml 142 143 140 141 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 155 156 152 153 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 227 228 222 223 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 267 268 256 257 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 282 283 270 271 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 315 316 303 304 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 338 339 326 327 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 351 352 339 340 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 357 358 345 346 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 363 364 351 352 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
Purified GST-PIKfyve bound to 5 muL of glutatione beads was incubated with inhibitors at fourfold dilutions over a concentration range of 5 mum to 0.001 mum in a total reaction volume of 25 muL. The assay buffer contained 10 mum ATP, 2 muCi of (gamma-32P) ATP, 100 mum PI-3P, 400 mum phosphatidyl-ethanolamine, 25 mm HEPES (pH 7.4), 120 mm NaCl, 1.5 mm MgCl2, 1 mm DTT, 0.5 mg/mL BSA and 2% dimethyl sulphoxide (DMSO). Reactions were terminated by spotting onto nitrocellulose membranes, which were then washed five or six times to remove unbound radioactivity and dried. Transferred radioactivity was quantitated using phosphorimaging, and IC50 values were calculated by fitting the data to a sigmoidal dose-response using Prism (GraphPad).
###end p 41
###begin title 42
Cell culture, PIKfyve inhibitor treatment and siRNA transfection
###end title 42
###begin p 43
###xml 45 46 45 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 490 491 490 491 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 536 537 536 537 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 739 740 739 740 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 121 125 <span type="species:ncbi:9913">calf</span>
HeLa and HEK293A cells were cultured in 5% CO2 in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% foetal calf serum and 1% non-essential amino acids. To retain expression of stably transfected constructs, culture medium for CD8 cell lines was supplemented with 0.5 mg/mL G418. On-Target Plus siRNA oligos against PIKfyve and Vac14 were purchased from Dharmacon. A 2-hit protocol over 72 h was used. Briefly, HeLa cells were seeded in six-well plates at a density of 2.4 x 105 cells/well. Cells were transfected with 40 nm of the corresponding oligo using oligofectamine (Invitrogen), 24 h later. After a further 24 h, cells were reseeded onto six-well plates at the same density or onto cover-lips at a density of 0.12 x 106 cells/well and transfected again with 40 nM oligos for 24 h. Cells were then processed for western blotting and immunofluorescence as described below.
###end p 43
###begin title 44
Growth factor stimulation and cell lysis
###end title 44
###begin p 45
###xml 259 260 259 260 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 283 284 283 284 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
Where indicated, cells were serum-starved for 16 h and then stimulated with 100 ng/mL EGF or hepatocyte growth factor (HGF). Cells were washed twice in ice-cold phosphate buffered saline solution and lysed in Nonidet P-40 lysis buffer (0.5% Nonidet P-40, 25 mm Tris/Cl, pH 7.5, 100 mm NaCl). Lysates were cleared by centrifugation, resuspended in 5x SDS-sample buffer and resolved by SDS-PAGE followed by immunoblotting for detection with a Licor Odyssey.
###end p 45
###begin title 46
Immunofluorescence
###end title 46
###begin p 47
Cells were processed for immunofluorescence by fixation in 3% paraformaldehyde (PFA) in PBS, permeabilized with 0.2% Triton-X-100, blocked in 0.2% fish skin gelatin in PBS and incubated with antibodies in blocking buffer. Secondary antibodies were conjugated to either AlexaFluor 488, 594 or 633. Cover-slips were imaged using a Leica confocal SP2 AOBS (HCX PL APO CS 63.0 x 1.40 oil objective).
###end p 47
###begin title 48
HRP Internalization and Electron microscopy (EM)
###end title 48
###begin p 49
###xml 260 261 254 255 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 408 409 402 403 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 410 411 404 405 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 610 611 604 605 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 619 620 613 614 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
Cells were incubated in 10 mg/mL HRP in serum-free medium at 37degreesC for 10 min, 1 h or 4 h. Subsequently, cells were washed three times in ice-cold PBS and fixed in 0.5% glutaraldehyde for 30 min. Cells were washed three times at room temperature with 0.1 m Tris-Cl pH 7.6, followed by incubation for 10 min in 0.1% diaminobenzidine (DAB, Sigma) in Tris buffer and then for 10 min in 0.1% DAB and 0.01% H202 in Tris buffer at room temperature in the dark. The reaction was terminated, by washing 3 x 5 min in Tris buffer, and then 2 x 5 min in PBS. Cells were then post-fixed in the dark on ice with 1% OsO4 in 0.1 m phosphate buffer pH 7.4 for 1 h. Subsequently, the cells were washed 3 x 30 mi in PBS, followed by 2 x 30 min in distilled water and then incubated in 5% uranyl acetate in 30% ethanol for 1 h. Samples were dehydrated by sequential 10-min ethanol washes in 30%, 60%, 70%, 80% and then twice in 100% ethanol, then infiltrated with a 1:1 ratio of resin to 100% ethanol for 30 min. The infiltration resin was then replaced with 100% resin and the flat-embedded samples were polymerized at 60degreesC for 2 to 3 days.
###end p 49
###begin title 50
Anti-CD8 uptake experiments
###end title 50
###begin p 51
###xml 231 232 231 232 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
HeLaM CD8-CIM6PR or CD8-Furin cells were seeded onto cover-slips and treated with either siRNA or PIKfyve inhibitor. Cover-slips were then transferred to a well containing 3 mL ice-cold dihydroxybenzoate (DHB) (DMEM containing 25 mm Hepes and 0.2% fatty-acid free BSA) for 15 min. CD8-CIM6PR and CD8-Furin receptors at the cell surface were labelled by placing cover-slips, cell side down, upon a 100 muL drop of DHB containing 1 mug monoclonal anti-CD8 antibody at 4degreesC, for 1 h. Cover-slips were washed twice in ice-cold PBS, and then transferred to pre-warmed growth medium for the indicated time periods to allow uptake of the anti-CD8 antibody to occur. At the assay endpoint, cells were fixed and processed for immunofluorescence as described earlier.
###end p 51
###begin title 52
Shiga toxin uptake assay
###end title 52
###begin p 53
###xml 40 44 40 44 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">(38)</xref>
The assay has been described previously (38). Briefly, HeLa cells were seeded onto cover-slips and treated with either siRNA or PIKfyve inhibitor as described earlier. Subsequently, cells were incubated on ice for 30 min with 2 mug/muL Cy3-STxB in DHB. The 0-min time-point was immediately fixed and the remaining cover-slips washed twice in ice-cold PBS, transferred to pre-warmed growth medium and returned to the incubator for the indicated time periods to allow uptake to proceed. At the assay endpoint, cells were fixed and processed for immunofluorescence as described earlier.
###end p 53
###begin title 54
Induction of autophagy and GFP-LC3 shift assay
###end title 54
###begin p 55
###xml 606 607 606 607 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 700 705 <span type="species:ncbi:9940">sheep</span>
HEK293A cells stably expressing GFP-LC3 were seeded onto 12-well plates and treated with siRNA or PIKfyve inhibitor as described above. To induce autophagy the growth medium was either replaced with fresh medium (fed) or cells were washed four times with Earl's buffered saline solution and then starved for 2 h in the final wash. Where indicated, Leupeptin was added to the starvation medium at a concentration of 0.25 mg/mL. Following starvation, cells were either fixed and processed for immunofluorescence or lysed in 1x SDS-sample buffer. After protein determination lysates were supplemented with 1 mm DTT and 0.1% bromophenol blue and resolved by SDS-PAGE for western blotting with polyclonal sheep anti-GFP antibodies, which were quantified using a Licor Odyssey instrument.
###end p 55
###begin p 56
This work was supported by a Wellcome Trust Studentship to J. L. S.U. is a CRUK senior research fellow. We are especially grateful to Dr. Frank Cooke for his advice and generous gift of PIKfyve.
###end p 56
###begin title 57
References
###end title 57
###begin article-title 58
Regulation of membrane traffic by phosphoinositide 3-kinases
###end article-title 58
###begin article-title 59
Phosphatidylinositol 3-kinase activity is required at a postendocytic step in platelet-derived growth-factor receptor trafficking
###end article-title 59
###begin article-title 60
Phosphatidylinositol 3-kinase activity is required for early endosome fusion
###end article-title 60
###begin article-title 61
Involvement of the endosomal autoantigen EEA1 in homotypic fusion of early endosomes
###end article-title 61
###begin article-title 62
Hrs sorts ubiquitinated proteins into clathrin-coated microdomains of early endosomes
###end article-title 62
###begin article-title 63
Recycle your receptors with retromer
###end article-title 63
###begin article-title 64
###xml 53 58 <span type="species:ncbi:4932">yeast</span>
###xml 85 110 <span type="species:ncbi:4896">Schizosaccharomyces pombe</span>
###xml 115 121 <span type="species:ncbi:10090">murine</span>
Complementation analysis in PtdInsP kinase deficient yeast mutants demonstrates that Schizosaccharomyces pombe and murine Fab1p homologues are phosphatidylinositol 3-phosphate 5-kinases
###end article-title 64
###begin article-title 65
PIKfyve: Partners, significance, debates and paradoxes
###end article-title 65
###begin article-title 66
###xml 96 101 <span type="species:ncbi:4932">yeast</span>
Novel PI(4)P 5-kinase homologue, Fab1p, essential for normal vacuole function and morphology in yeast
###end article-title 66
###begin article-title 67
Osmotic stress activates phosphatidylinositol-3,5-bisphosphate synthesis
###end article-title 67
###begin article-title 68
The identification of phosphatidylinositol 3,5-bisphosphate in T-lymphocytes and its regulation by interleukin-2
###end article-title 68
###begin article-title 69
###xml 24 48 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
A mammalian ortholog of Saccharomyces cerevisiae Vac14 that associates with and up-regulates PIKfyve phosphoinositide 5-kinase activity
###end article-title 69
###begin article-title 70
Osmotic stress-induced increase of phosphatidylinositol 3,5-bisphosphate requires Vac14p, an activator of the lipid kinase Fab1p
###end article-title 70
###begin article-title 71
Vac14 controls PtdIns(3,5)P(2) synthesis and Fab1-dependent protein trafficking to the multivesicular body
###end article-title 71
###begin article-title 72
Phosphatidylinositol 3,5-bisphosphate: metabolism and cellular functions
###end article-title 72
###begin article-title 73
Svp1p defines a family of phosphatidylinositol 3,5-bisphosphate effectors
###end article-title 73
###begin article-title 74
PtdIns-specific MPR pathway association of a novel WD40 repeat protein, WIPI49
###end article-title 74
###begin article-title 75
###xml 87 111 87 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Saccharomyces cerevisiae</italic>
###xml 116 131 116 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pichia pastoris</italic>
###xml 87 111 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
###xml 116 131 <span type="species:ncbi:4922">Pichia pastoris</span>
Cvt18/Gsa12 is required for cytoplasm-to-vacuole transport, pexophagy and autophagy in Saccharomyces cerevisiae and Pichia pastoris
###end article-title 75
###begin article-title 76
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human WIPI-1 puncta-formation: a novel assay to assess mammalian autophagy
###end article-title 76
###begin article-title 77
###xml 84 106 84 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Caenorhabditis elegans</italic>
###xml 84 106 <span type="species:ncbi:6239">Caenorhabditis elegans</span>
The phosphoinositide kinase PIKfyve/Fab1p regulates terminal lysosome maturation in Caenorhabditis elegans
###end article-title 77
###begin article-title 78
Fab1 phosphatidylinositol 3-phosphate 5-kinase controls trafficking but not silencing of endocytosed receptors
###end article-title 78
###begin article-title 79
###xml 121 125 <span type="species:ncbi:10090">mice</span>
Loss of Vac14, a regulator of the signaling lipid phosphatidylinositol 3,5-bisphosphate, results in neurodegeneration in mice
###end article-title 79
###begin article-title 80
The mammalian phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) regulates endosome-to-TGN retrograde transport
###end article-title 80
###begin article-title 81
A selective PIKfyve inhibitor blocks PtdIns(3,5)P(2) production and disrupts endomembrane transport and retroviral budding
###end article-title 81
###begin article-title 82
TGN38/41 recycles between the cell surface and the TGN: brefeldin A affects its rate of return to the TGN
###end article-title 82
###begin article-title 83
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human autoantibodies as reagents to conserved Golgi components. Characterization of a peripheral, 230-kDa compartment-specific Golgi protein
###end article-title 83
###begin article-title 84
The retromer complex and clathrin define an early endosomal retrograde exit site
###end article-title 84
###begin article-title 85
Cargo-selective endosomal sorting for retrieval to the Golgi requires retromer
###end article-title 85
###begin article-title 86
EEA1, an early endosome-associated protein
###end article-title 86
###begin article-title 87
The interface of receptor trafficking and signalling
###end article-title 87
###begin article-title 88
Molecular dissection of autophagy: two ubiquitin-like systems
###end article-title 88
###begin article-title 89
Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes
###end article-title 89
###begin article-title 90
Methods for monitoring autophagy
###end article-title 90
###begin article-title 91
siRNA screening of the kinome identifies ULK1 as a multidomain modulator of autophagy
###end article-title 91
###begin article-title 92
###xml 52 57 <span type="species:ncbi:4932">yeast</span>
Localization of phosphatidylinositol 3-phosphate in yeast and mammalian cells
###end article-title 92
###begin article-title 93
A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling
###end article-title 93
###begin article-title 94
Pd-catalyzed intermolecular amidation of aryl halides: the discovery that xantphos can be trans-chelating in a palladium complex
###end article-title 94
###begin article-title 95
Specific Rab GTPase-activating proteins define the Shiga toxin and epidermal growth factor uptake pathways
###end article-title 95

